Remsima
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Introduccion: las terapias biologicas, particularmente agentes anti-TNF alfa, han revolucionado el enfoque terapeutico de la…
Background: The use of biological agents, namely anti-TNF monoclonal antibodies, has dramatically changed the management of…
Background: At the time, few data have been published on infliximab biosimilar’s efficacy and safety in patients with Crohn’s…
Biosimilars came into existence with the sole ideology of affordable medication for chronic illnesses in the therapy areas of…
455 Remicade in Europe, saw sales of the drug drop to $1.79 billion last year from $2.3 billion in the previous year. In a…
Two biosimilar TNF-alfa monoclonal antibody (mAb) products were approved for clinical use in the European Union on 10 September…
The first biosimilar versions of a monoclonal antibody have received a positive opinion from the European Medicines Agency (EMA…
Dostępność leków biopodobnych o porównywalnej skuteczności i bezpieczeństwie przy niższej cenie może zwiększyć liczbę chorych…